| Original language | English |
|---|---|
| Pages (from-to) | 680-686 |
| Number of pages | 7 |
| Journal | International Journal of STD and AIDS |
| Volume | 29 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published (VoR) - 1 Jun 2018 |
Funding
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All authors were in receipt of a paid consultancy for this study. CAI is in receipt of a patent for the Mycoplasma genitalium detection assay based on MG219 gene (PCT/GB2007/001913 and foreign equivalents). HF is a member of the Scientific Advisory Board for Discuva Ltd. PH had non-financial support from Hologic, during the conduct of the study; personal fees from Crown Prosecution service, personal fees from British Association for Sexual Health and HIV, grants from Mast Group Ltd, non-financial support from Hologic, outside the submitted work. In addition, PH has a patent A sialidase spot test to diagnose bacterial vaginosis issued to University of Bristol. PM has been in receipt of grants, conference expenses and consultancy fees from Hologic Inc and grants from Elitech UK Ltd. JN has received fees from Hologic for conference presentations. KR is a consultant to Hologic. JR has been in receipt of a paid consultancy for GSK pharma and for Hologic. DTR has no other competing interests. JW has previously received research and educational support and hospitality from BD Diagnostics, Genprobe/Hologic, Abbott Diagnostics, Alere, Viiv, Gilead, Boerhinger Ingelheim, Abbott Pharmaceuticals, Diagnostics Development Unit/DRW, University of Cambridge, and is an Editor in Chief of International Journal of STD & AIDS, SAGE publishing.
Keywords
- Chlamydia
- Mycoplasma genitalium
- genito-urinary medicine
- testing
- urethritis